Answer
No metabolic drug–drug interactions are expected with pembrolizumab because it is cleared through catabolism, although no formal pharmacokinetic drug interaction studies have been conducted.
Sources for this answer
- KEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 67Document updated
Sources checked